Xu Zhengchao, Preda Veronica, Jabbour James
Faculty of Medicine and Health Sciences, Macquarie University Hospital, Sydney, NSW, Australia.
Sydney Eye Specialists, Sydney, NSW, Australia.
Case Rep Ophthalmol. 2023 Apr 28;14(1):185-193. doi: 10.1159/000530221. eCollection 2023 Jan-Dec.
This is a case of ezetimibe-induced concentric field loss, dyschromatopsia, and nyctalopia in a patient with no prior history of retinal dystrophy or drug hypersensitivity. A 55-year-old Caucasian woman presents with a 1-year history of increasing concentric visual field loss, nyctalopia, photophobia, and colour vision impairment. These symptoms correlated with the commencement of ezetimibe therapy 10 mg daily for hypercholesterolaemia. She demonstrated repeatable bilateral visual field constriction on 30-2 Humphrey visual filed testing and colour vision impairment on Ishihara plates (OD: 1/17, OS: 1/17). Biochemical and radiological screening for carcinoma-associated retinopathy was unremarkable. A working diagnosis of drug-induced rod-cone dysfunction was made. Her visual symptoms and field changes completely resolved 3 months after cessation of ezetimibe therapy. This case suggests that ezetimibe is a potential cause of rod-cone dysfunction and should be considered as a differential in patients with new unexplained visual symptoms.
这是一例依折麦布诱发的同心性视野缺损、色觉障碍和夜盲症病例，该患者既往无视网膜营养不良或药物过敏史。一名55岁的白种女性，有1年渐进性同心性视野缺损、夜盲症、畏光和色觉障碍病史。这些症状与因高胆固醇血症开始每日服用10mg依折麦布治疗相关。在30-2 Humphrey视野检查中，她表现出可重复性双侧视野收缩，在石原氏色盲测验中有色觉障碍（右眼：1/17，左眼：1/17）。针对癌相关性视网膜病变的生化和放射学筛查无异常。做出了药物性视杆-视锥细胞功能障碍的初步诊断。在停用依折麦布治疗3个月后，她的视觉症状和视野改变完全消失。该病例表明，依折麦布是视杆-视锥细胞功能障碍的一个潜在原因，对于有新的不明原因视觉症状的患者应考虑将其作为鉴别诊断因素。
